In addition, chemotherapeutic regimens, especially cyclophosphamide, are commonly used in combination with growth factors for autologous HSCs mobilization, which could improve CD34+ cells yield and reduce tumor cells burden, but with the expense of increased toxicity [18]. Here, CD34 is linked to neoplasm.